ArticleGenes & diseases2026
Identifying C1orf122 as a potential HCC exacerbated biomarker dependently of SRPK1 regulates PI3K/AKT/GSK3β signaling pathway.
Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial phosphoproteomics reveals regional phosphorylation features in liver cirrhosis progression.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Chromosome 1 open reading frame 122 (C1orf122) is known to be a protein-coding gene, its biological functions and mechanisms in hepatocellular carcinoma (HCC) remain unknown. Herein, bioinformatics analysis and experimental validation revealed that, C1orf122 was overexpressed in HCC tissues and cells, and correlated strongly with a poor prognosis of HCC patients. Subsequently, we knocked down and overexpressed C1orf122 in HCC cells, confirmed that C1orf122 significantly stimulated HCC cell growth and proliferation. Furthermore, flow cytometry and WB detection confirmed that C1orf122 significantly suppressed HCC cell apoptosis. Transwell migration and wound healing assays, along with WB analysis showed that C1orf122 strongly improved HCC cell migratory capacity. Mass spectrometry (MS) and Co-Immunoprecipitation (Co-IP) assays identified serine/arginine-rich protein-specific kinase 1 (SRPK1) as a C1orf122-interacting protein. Moreover, C1orf122 significantly upregulated total SRPK1 levels and suppressed SRPK1 protein phosphorylation at the Thr601 site. Using online prediction tools, we found that mTOR was the kinase of SRPK1 phosphorylating it at the Thr601 site, and other experiments confirmed that C1orf122 mediated SRPK1 Thr601 phosphorylation in a mTOR kinase-dependent manner. The cell phenotype assays further revealed that SRPK1 strongly stimulated the PI3K/AKT/GSK3β signaling pathway to enhance cell growth and migration. It was also observed that C1orf122 significantly activated the PI3K/AKT/GSK3β signaling pathway via SRPK1. To the best of our knowledge, this is the first study to demonstrate the involvement of the C1orf122-SRPK1-PI3K/AKT/GSK3β axis in HCC growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.